✦ LIBER ✦

Modeling of treatment response to erythropoiesis-stimulating agents in older (age≥70years) and younger (age<70years) patients with cancer and anemia: Findings from the Anemia Cancer Treatment study

✍ Scribed by Abraham, Ivo; MacDonald, Karen; Tharmarajah, Soba; Bokemeyer, Carsten; Ludwig, Heinz; Soubeyran, Pierre; Battistel, Vittorio; Aapro, Matti

Book ID: 122917182
Publisher: Elsevier
Year: 2013
Tongue: English
Weight: 216 KB
Volume: 4
Category: Article
ISSN: 1879-4068
DOI: 10.1016/j.jgo.2012.09.058

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase 2 trial of docetaxel and gefitinib

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older

✍ George R. Simon; Martine Extermann; Alberto Chiappori; Charles C. Williams; Mube 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

## Abstract ## BACKGROUND This is a phase 2 study of chemotherapy‐naive patients, 70 years of age or older, with nonsmall‐cell lung cancer (NSCLC) who were treated with docetaxel and gefitinib. The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progress